Indications/Usage:

Adult Rheumatoid Arthritis (RA): ORENCIA® (abatacept) is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. ORENCIA may be used as monotherapy or concomitantly with disease-modifying, anti-rheumatic drugs (DMARDs) other than tumor necrosis factor (TNF) antagonists.

Juvenile Idiopathic Arthritis (JIA): ORENCIA is also indicated for reducing signs and symptoms in pediatric patients aged 6 years and older with moderately to severely active polyarticular JIA. ORENCIA may be used as monotherapy or concomitantly with methotrexate (MTX).

Important Limitations of Use:

ORENCIA should not be administered concomitantly with TNF antagonists, and is not recommended for use concomitantly with other biologic RA therapy, such as anakinra.

  • Access Support™, the Bristol-Myers Squibb reimbursement services program, offers patient assistance support, benefits investigation, prior authorization support and appeals assistance. Program counselors are available Monday through Friday, from 8:00 A.M. to 8:00 P.M. ET at 1-800-861-0048, to support the rheumatology offices' reimbursement services needs of their insured and uninsured patients.
    You can also find information online at www.bmsaccesssupport.com.

    Learn more